Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | The prognostic and potentially therapeutic value of liquid biopsy in multiple myeloma

Nicholas Bingham • 28 Sep 2023
IMS 2023
Multiple Myeloma

Nicholas Bingham, MBBS, FRACP, FRCPA, Alfred Health & Monash University, Melbourne, Australia, discusses the prognostic and therapeutic value of liquid biopsy in multiple myeloma, and further highlights how this approach may be used to highlight mutations in cell-free DNA (cfDNA) and better predict patient response to therapy. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Celgene/BMS – travel support
Janssen – honorarium

More from Nicholas Bingham

2:00
The role of small nucleotide, copy number and structural variants in extramedullary myeloma
Nicholas Bingham • 28 Sep 2023
1:23
Evaluating the sensitivity of liquid biopsy in patients with extramedullary multiple myeloma
Nicholas Bingham • 28 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals